Pierre Fabre

Pierre Fabre

Allogeneic cell therapies development and commercialization

Overview

Pierre Fabre Pharmaceuticals (US) develops and commercializes allogeneic cell therapies for oncology and rare diseases. It focuses on bringing next-generation, donor-derived cell therapies to patients with high unmet medical needs and deepens partnerships with biotech companies to advance products through clinical manufacturing and distribution in the US.

About Pierre Fabre

Simplify's Rating
Why Pierre Fabre is rated
C
Rated C on Competitive Edge
Rated C on Growth Potential
Rated C on Differentiation

Industries

Biotechnology

Healthcare

Company Size

5,001-10,000

Company Stage

Seed

Total Funding

$13.8M

Headquarters

Toulouse, France

Founded

1951

Simplify Jobs

Simplify's Take

What believers are saying

  • Oncology receives over 80% of pipeline investment.
  • BRAFTOVI and MEKTOVI extend targeted oncology reach.
  • Rare-disease partnerships create multiple licensing and co-development paths.

What critics are saying

  • Pipeline depends on external partners for key assets.
  • Narrow rare-disease markets limit revenue scale.
  • Allogeneic cell therapy faces manufacturing and clinical setbacks.

What makes Pierre Fabre unique

  • US subsidiary focused on oncology and rare diseases.
  • Builds pipeline through R&D and BD&L partnerships.
  • Allogeneic T-cell therapy targets EBV+ PTLD.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$13.8M

Above

Industry Average

Funded Over

1 Rounds

Seed funding is usually the first official round after pre-seed, when a startup has a prototype or concept. It’s typically used to develop the product, test the market, and start building the team. Investors here are often angel investors or early-stage venture capitalists.
Seed Funding Comparison
Above Average

Industry standards

$3.3M
$2M
Netflix
$2.3M
Instacart
$3M
Robinhood
$13.8M
Pierre Fabre

Company News

PR Newswire
Mar 11th, 2026
Avène uses AI to expand acne clinical study from 100 to 600 patients

Pierre Fabre Laboratories' brand Avène is using artificial intelligence to enhance clinical studies for acne treatments. In partnership with Toulouse-based HealthTech company BotDesign, the brand is employing data augmentation to expand patient data from 100 to 600 participants, strengthening the robustness of its research. In 2026, Avène will conduct a comparative clinical study evaluating its new treatment, Cleanance Comedomed+, for acne-prone skin in the maintenance phase following oral isotretinoin treatment in adults with severe to very severe acne. The initiative represents a breakthrough in dermo-cosmetics clinical studies, allowing the leading French pharmacy brand to support more patients whilst improving research quality through AI-powered data enhancement.

Top Class Actions
Dec 19th, 2025
Class action claims Avène products falsely advertised as '0% preservative'

Class action claims Avène products falsely advertised as '0% preservative' Edited by: top class actions | december 19, 2025. Pierre Fabre class action lawsuit overview: * Who: Plaintiff Ivy-Karina Vales filed a class action lawsuit against Pierre Fabre USA Inc. and Pierre Fabre Dermo-Cosmetique USA Inc. * Why: Vales claims the companies falsely advertise that their Avène skincare products are preservative-free. * Where: The Piere Fabre class action lawsuit was filed in California federal court. A new class action lawsuit claims Pierre Fabre USA falsely advertises that its Avène skincare products are preservative-free. Plaintiff Ivy-Karina Vales filed the class action complaint against Pierre Fabre USA and Pierre Fabre Dermo-Cosmetique USA on Dec. 8 in California federal court, alleging violations of state and federal consumer laws. According to the class action lawsuit, the companies falsely advertise their Avène skincare products as preservative-free despite containing a well-known preservative. Vales claims the companies mislead consumers into paying a premium for products they believe are preservative-free, causing financial harm to consumers who prefer such products. As a result, Vales says she and other consumers are entitled to compensation for the price premium they paid for the products. She also seeks injunctive relief to prevent Pierre Fabre from continuing to market the products as preservative-free. Avène skincare products contain citric acid, lawsuit claims. According to the class action lawsuit, Pierre Fabre's Avène skincare products are marketed as preservative-free, leading consumers to believe they are purchasing premium products. "Defendants falsely and deceptively advertise the products as 'preservative-free' and/or '0% preservative,'" Vales says. "However, contrary to the products' Challenged Representations, the products actually contain citric acid - a well-defined artificial preservative ingredient commonly used in cosmetic products." Vales claims Pierre Fabre's advertising exploits consumers' desire for preservative-free products, allowing the company to charge higher prices. She says she and other consumers relied on the company's advertising when purchasing the products, believing they were free of preservatives. If consumers had known the products contained preservatives, they would not have purchased them or would have paid less, she alleges. Recently, various lawsuits have targeted the use of citric acid in "all natural" or "preservative free" claims. Frito-Lay is facing class action allegations over the use of citric acid in its Poppables snack, while Big Heart Pet Brands is accused of falsely advertising its Milk-Bone Dipped dog biscuits for the same reason. What do you think of the allegations made in this Avène skincare class action lawsuit? Let us know in the comments. The plaintiff is represented by Valter Malkhasyan and Erik Pogosyan of Malk & Pogo Law Group LLP. The Avène Fabre class action lawsuit is Vales v. Pierre Fabre USA Inc., et al., Case No. 5:25-cv-10523, in the U.S. District Court for the Northern District of California. Don't miss out! Read About More Class Action Lawsuits & Class Action Settlements:

Pierre Fabre
Jun 20th, 2025
Audrey Ricard Campion joins Pierre Fabre Laboratories as Head of Research and Development Dermo-Cosmetics

Audrey Ricard Campion joins Pierre Fabre Laboratories as Head of Research and Development dermo-cosmetics.

Startupticker.ch
Jun 2nd, 2025
French pharma giant acquires Basel based Vertical Bio

Last year, Versant Ventures, through its Ridgeline Discovery Engine, spun out two biotech startups successfully. The journey for Its third venture, Vertical bio, which develops of novel cancer therapies, has been short: the company has been acquired by Pierre Fabre Laboratories, a €2.7 billion French medical and beauty care company.

PRWeek
Sep 24th, 2024
Porter Novelli hires Sarah DaVanzo as chief innovation officer

DaVanzo joined Porter from pharmaceutical company Pierre Fabre Group, where she served as chief consumer engagement and activation officer and was responsible for AI, analytics, insights, foresight and marketing services innovation and execution.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Pierre Fabre right now.

Find jobs on Simplify and start your career today

We update Pierre Fabre's jobs every few hours, so check again soon! Browse all jobs →